PRELIMINARY RESULTS OF PHASE I COMBINATION STUDY OF ERIBULIN MESYLATE WITH TRASTUZUMAB IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR 2 (HER2) POSITIVE ADVANCED OR METASTATIC BREAST CANCER

被引：0
|
作者：
Sasaki, Y. [1 ]
Miwa, K. [1 ]
Araki, K. [1 ]
Matsubara, N. [2 ]
Naito, Y. [2 ]
Obaishi, H.
Namiki, M.
Ishikawa, K.
Mukai, H. [2 ]
机构：
[1] Saitama Int Med Ctr, Ctr Comprehens Canc, Saitama, Japan
[2] Natl Canc Ctr Hosp E, Div Hematol Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [1] Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer
    Kawaguchi, Hidetoshi
    Yamashita, Toshinari
    Masuda, Norikazu
    Kitada, Masahiro
    Narui, Kazutaka
    Hattori, Masaya
    Yoshinami, Tetsuhiro
    Matsunami, Nobuki
    Yanagihara, Kazuhiro
    Kawasoe, Teru
    Nagashima, Takeshi
    Bando, Hiroko
    Yano, Hiroshi
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    CANCER RESEARCH, 2018, 78 (04)
  • [2] A phase I combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2-positive (HER2+) breast cancer
    Mukai, H.
    Shimada, K.
    Naito, Y.
    Matsubara, N.
    Nakanishi, T.
    Obaishi, H.
    Namiki, M.
    Narita, T.
    Masuda, M.
    Sasaki, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S414 - S414
  • [3] Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
    Hirofumi Mukai
    Toshiaki Saeki
    Ken Shimada
    Yoichi Naito
    Nobuaki Matsubara
    Tadashi Nakanishi
    Hiroshi Obaishi
    Masayuki Namiki
    Yasutsuna Sasaki
    Investigational New Drugs, 2015, 33 : 119 - 127
  • [4] Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
    Mukai, Hirofumi
    Saeki, Toshiaki
    Shimada, Ken
    Naito, Yoichi
    Matsubara, Nobuaki
    Nakanishi, Tadashi
    Obaishi, Hiroshi
    Namiki, Masayuki
    Sasaki, Yasutsuna
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 119 - 127
  • [5] A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
    Luis, Ines Maria Vaz Duarte
    Guo, Hao
    Barry, William Thomas
    Krop, Ian E.
    Wagle, Nikhil
    Lowe, Alarice
    Gore, Danielle
    Andrews, Chelsea
    Osmani, Wafa
    Isakoff, Steven J.
    Tung, Nadine M.
    Winer, Eric P.
    Lin, Nancy U.
    Freedman, Rachel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer
    Freedman, Rachel A.
    Luis, Ines Maria Vaz Duarte
    Barry, William Thomas
    Krop, Ian E.
    Wagle, Nikhil
    Lowe, Alarice
    Galler, Sarah
    Sohl, Jessica
    Isakoff, Steven J.
    Tung, Nadine M.
    Winer, Eric P.
    Lin, Nancy U.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer (SONG-02)
    Abe, Hajime
    Kamigaki, Shunji
    Komoike, Yoshifumi
    Matsunami, Nobuki
    Nakano, Yoshiaki
    Tezuka, Kenji
    Tsurutani, Junji
    Yamamura, Jun
    Yamazaki, Keiichi
    CANCER RESEARCH, 2015, 75
  • [8] A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Komal Jhaveri
    Rui Wang
    Eleonora Teplinsky
    Sarat Chandarlapaty
    David Solit
    Karen Cadoo
    James Speyer
    Gabriella D’Andrea
    Sylvia Adams
    Sujata Patil
    Sofia Haque
    Tara O’Neill
    Kent Friedman
    Francisco J. Esteva
    Clifford Hudis
    Shanu Modi
    Breast Cancer Research, 19
  • [9] A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Jhaveri, Komal
    Wang, Rui
    Teplinsky, Eleonora
    Chandarlapaty, Sarat
    Solit, David
    Cadoo, Karen
    Speyer, James
    D'Andrea, Gabriella
    Adams, Sylvia
    Patil, Sujata
    Haque, Sofia
    O'Neill, Tara
    Friedman, Kent
    Esteva, Francisco J.
    Hudis, Clifford
    Modi, Shanu
    BREAST CANCER RESEARCH, 2017, 19
  • [10] Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer
    Gil, M.
    Martin, M.
    Antolin, S.
    Trigo, J. M.
    Guerrero, A.
    Vidal, L.
    Urruticoechea, A.
    Pandiella, A.
    Hernando, A.
    Ocana, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S180
12345